Comera Life Sciences Holdings (Comera Life Sciences Holdings) Forward Dividend Yield % : 0.00% (As of Jun. 03, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Forward Dividend Yield %?

As of today (2024-06-03), the Forward Annual Dividend Yield of Comera Life Sciences Holdings is 0.00%.

As of today (2024-06-03), the Trailing Annual Dividend Yield of Comera Life Sciences Holdings is 0.00%.

CMRA's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.57
* Ranked among companies with meaningful Forward Dividend Yield % only.

Comera Life Sciences Holdings's Dividends per Share for the three months ended in Sep. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Comera Life Sciences Holdings's Forward Dividend Yield %

For the Biotechnology subindustry, Comera Life Sciences Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Comera Life Sciences Holdings's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Forward Dividend Yield % falls into.

Comera Life Sciences Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Comera Life Sciences Holdings (OTCPK:CMRA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Comera Life Sciences Holdings Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Gill Street, Suite 4650, Woburn, MA, USA, 01801

Website

https://www.comeralifesciences.com

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Executives

Michael Gerard Campbell	officer: Chief Financial Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
David Soane	10 percent owner	C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney	officer: Chief Scientific Officer	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck	director	C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle	director	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr.	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt	officer: Chief Business Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman	director, officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni	officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp	10 percent owner	36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065